Myriad Genetics (NASDAQ:MYGN) Given New $14.00 Price Target at Piper Sandler
Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its target price cut by analysts at Piper Sandler from $24.00 to $14.00 in a research note issued on Thursday,Benzinga reports. The brokerage ...
Consumer Genomics Market Size to Hit USD 10.8 Billion by 2032, Growing at a 24.6% CAGR - SNS Insider
Consumer Genomics Market growth is driven by rapid advancements in genetic testing technologies, declining sequencing costs, and increasing consumer awarenessPune, Jan. 31, 2025 (GLOBE NEWSWIRE) -- ...
Cancer Genetic Testing Market Size to Worth USD 17.98 Billion by 2033 | Straits Research
The global cancer genetic testing market size was valued at USD 6.70 billion in 2024 and is projected to reach from USD 7.47 billion in 2025 to USD 17.98 billion by 2033, growing at a CAGR of 11.6% ...
Zacks.com on MSN3d
Is QIAGEN Stock an Apt Pick for Your Portfolio Right Now?
QIAGEN N.V.’s QGEN long-term business strategy focuses on forming partnerships for the development, commercialization, marketing and distribution of existing and future products. The company sees ...
Myriad Genetics price target lowered to $14 from $24 at Piper Sandler
Piper Sandler analyst David Westenberg lowered the firm’s price target on Myriad Genetics (MYGN) to $14 from $24 and keeps a Neutral rating on ...
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
The study found that Prequel ® Prenatal Screen with AMPLIFY™ technology enables reliable results as early as eight-weeks’ gestation. Typically, prenatal cell-free DNA (pcfDNA) screening is offered ...
bovnews4d
The Myriad Genetics Inc Enigma: What’s Causing the Wild Swings in MYGN Stock?
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 3.75% of ...
The Bakersfield Californian4d
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at ...